 |
|
Use and Monitoring of "Statin" Lipid-Lowering Drugs Compared With Guidelines
Susan A. Abookire, MD, MPH;
Andrew S. Karson, MD;
Julie Fiskio;
David W. Bates, MD, MSc
Arch Intern Med. 2001;161:53-58.
Background In patients with high cholesterol, 3-hydroxy-3-methylglutaryl coenzyme
A reductase inhibitors (or "statins") have been shown to reduce overall mortality
in primary and secondary prevention. The National Cholesterol Education Program
expert panel's guidelines (Adult Treatment Panel II) recommend evaluation
and treatment of high cholesterol based on stratification of patients according
to cardiovascular risk. While evidence suggests that many patients are undertreated,
comparatively few data are available regarding overtreatment.
Objectives To assess the appropriateness of statin therapy compared with national
guidelines and to examine the appropriateness of monitoring for adverse effects.
Methods For all patients at a tertiary medical center, electronic medical records
were evaluated for presence or absence of statin use and for presence of established
coronary heart disease or cardiac risk factors. Therapy was compared with
the recommendations of the National Cholesterol Education Program guidelines.
Our primary outcome measures included, for all patients taking statins, prevalence
of appropriateness vs overuse, and for all patients with coronary heart disease,
prevalence of appropriateness vs underuse.
Results Overuse of statin therapy was found among 69% of patients undergoing
primary prevention, and among 47% of patients undergoing secondary prevention.
In addition, among patients with coronary heart disease who were not taking
statins, 88% were undertreated. Monitoring of liver function varied widely,
and did not correlate with the risk of adverse events secondary to statin
use.
Conclusions Overtreatment and undertreatment for hyperlipidemia were frequent. Decision
support may help physicians improve their performance compared with guidelines.
From the Division of General Medicine, Department of Medicine, Brigham
and Women's Hospital and Harvard Medical School (Drs Abookire, Karson, and
Bates), and Partners Information Systems (Drs Abookire and Bates and Ms Fiskio),
Boston, Mass.
Corresponding author and reprints: Susan A. Abookire, MD, MPH, Division
of General Medicine, Department of Medicine, Brigham and Women's Hospital,
75 Francis St, Boston, MA 02115 (e-mail: sabookire{at}partners.org).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTER
Appropriate Use of Statin Drugs
Michael Pignone
Arch Intern Med. 2001;161(21):2626-2627.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2001;161(1):131-132.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Compliance with Platelet Count Monitoring Recommendations and Management of Possible Heparin-Induced Thrombocytopenia in Hospitalized Patients Receiving Low-Molecular-Weight Heparin
ten Berg et al.
The Annals of Pharmacotherapy 2009;43:1405-1412.
ABSTRACT
| FULL TEXT
Optimizing the Start Time of Statin Therapy for Patients with Diabetes
Denton et al.
Med Decis Making 2009;29:351-367.
ABSTRACT
A Randomized Trial of Electronic Clinical Reminders to Improve Medication Laboratory Monitoring
Matheny et al.
J. Am. Med. Inform. Assoc. 2008;15:424-429.
ABSTRACT
| FULL TEXT
Risk factor awareness and secondary prevention of coronary artery disease: are we doing enough?
Karthik et al.
ICVTS 2006;5:268-271.
ABSTRACT
| FULL TEXT
Adherence to black box warnings for prescription medications in outpatients.
Lasser et al.
Arch Intern Med 2006;166:338-344.
ABSTRACT
| FULL TEXT
Dyslipidemia Prevalence, Treatment, and Control in the Multi-Ethnic Study of Atherosclerosis (MESA): Gender, Ethnicity, and Coronary Artery Calcium
Goff et al.
Circulation 2006;113:647-656.
ABSTRACT
| FULL TEXT
Improving Laboratory Monitoring at Initiation of Drug Therapy in Ambulatory Care: A Randomized Trial
Raebel et al.
Arch Intern Med 2005;165:2395-2401.
ABSTRACT
| FULL TEXT
Adherence to Heart Failure Quality-of-Care Indicators in US Hospitals: Analysis of the ADHERE Registry
Fonarow et al.
Arch Intern Med 2005;165:1469-1477.
ABSTRACT
| FULL TEXT
Physiological Mechanisms for the Seasonal Changes in Serum Cholesterol Level--Reply
Ockene et al.
Arch Intern Med 2004;164:2506-2507.
FULL TEXT
Linking Laboratory and Pharmacy: Opportunities for Reducing Errors and Improving Care
Schiff et al.
Arch Intern Med 2003;163:893-900.
ABSTRACT
| FULL TEXT
Secondary prevention after coronary bypass: the American Heart Association "Get with the Guidelines" program
Denton et al.
Ann. Thorac. Surg. 2003;75:758-760.
FULL TEXT
The Business Case For Quality: Case Studies And An Analysis
Leatherman et al.
Health Aff (Millwood) 2003;22:17-30.
ABSTRACT
| FULL TEXT
Determination of Lipid Profiles and Use of Statins in Patients With Ischemic Stroke or Transient Ischemic Attack
Lalouschek et al.
Stroke 2003;34:105-110.
ABSTRACT
| FULL TEXT
Statin treatment following coronary artery stenting and one-year survival
Schomig et al.
J Am Coll Cardiol 2002;40:854-861.
ABSTRACT
| FULL TEXT
Disparities in the Diagnosis and Pharmacologic Treatment of High Serum Cholesterol by Race and Ethnicity: Data From the Third National Health and Nutrition Examination Survey
Nelson et al.
Arch Intern Med 2002;162:929-935.
ABSTRACT
| FULL TEXT
Appropriate Use of Statin Drugs
Pignone
Arch Intern Med 2001;161:2626-2627.
FULL TEXT
|
